Biohaven crashes 44% after FDA rejects Vyglxia drug
Biohaven (BHVN) shares plunged 44% after the FDA rejected its drug Vyglxia for spinocerebellar ataxia, citing study bias, design flaws, and unmeasured confounding factors. The company said it will seek a meeting with the FDA to discuss next steps and may pause non-priority programs to preserve cash.